Vigil Neuroscience, Inc. has 4 Schedule 13D or 13G filings on record since 2025-08-07. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Glazer Capital, LLC | 6.45% | 3,012,068 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Atlas Venture Fund XII, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-08-07 | 2025-08-05 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Beryl Capital Management LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Purpose of Transaction (Item 4)
Atlas Venture Fund XII, L.P.
Item 4 of the Statement is hereby amended and supplemented as follows: On May 21, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sanofi, a French societe anonyme ("Parent" or "Sanofi"), and Vesper Acquisition Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which, Merger Sub would merge with and into the Issuer (the "Merger"), with the Issuer surviving the merger as a wholly-owned subsidiary of Parent. On August 4, 2025, at a special meeting of stockholders of the Issuer, the Issuer's stockholders voted to adopt the Merger Agreement. On August 5, 2025, the Merger closed and each share of the Issuer's Common Stock issued and outstanding, including all of the shares of Common Stock owned by the Reporting Persons, was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.Item 4 of the SCHEDULE 13D/A filed 2025-08-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Atlas Venture Fund XII, L.P. | 0% | SCHEDULE 13D/A |
| 2025-08-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Glazer Capital, LLC | 6.45% | SCHEDULE 13G/A |
| 2025-11-14 | Beryl Capital Management LLC | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Vigil Neuroscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.